These two firms have successful drugs and could make nice additions for larger companies.
The oncology company already has risen significantly this year, but its charts indicate the rally could continue.
Initial inquiry into deal showed it could remove what might be most significant competitive threat to Illumina.
Investors and traders should approach MRK from the long side.
I'm inclined to add to Disney on today's weakness.
The company is testing its hematologic malignancies treatment.
Kura Oncology climbs after the clinical-stage biopharmaceutical company says a phase 2 trial of its lymphoma treatment tipifarnib showed encouraging results.
TheStreet’s Fundamentals of Investing Course will teach you the keys to making the right decisions in any market.
TheStreet’s Personal Finance Essentials Course will teach you money management basics and investing strategies to help you avoid major financial pitfalls.
TheStreet Courses offers dedicated classes designed to improve your investing skills, stock market knowledge and money management capabilities.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.